Systematic Analysis of Splice-Site-Creating Mutations in Cancer

The Cancer Genome Atlas Research Network

Research output: Contribution to journalArticle

Abstract

For the past decade, cancer genomic studies have focused on mutations leading to splice-site disruption, overlooking those having splice-creating potential. Here, we applied a bioinformatic tool, MiSplice, for the large-scale discovery of splice-site-creating mutations (SCMs) across 8,656 TCGA tumors. We report 1,964 originally mis-annotated mutations having clear evidence of creating alternative splice junctions. TP53 and GATA3 have 26 and 18 SCMs, respectively, and ATRX has 5 from lower-grade gliomas. Mutations in 11 genes, including PARP1, BRCA1, and BAP1, were experimentally validated for splice-site-creating function. Notably, we found that neoantigens induced by SCMs are likely several folds more immunogenic compared to missense mutations, exemplified by the recurrent GATA3 SCM. Further, high expression of PD-1 and PD-L1 was observed in tumors with SCMs, suggesting candidates for immune blockade therapy. Our work highlights the importance of integrating DNA and RNA data for understanding the functional and the clinical implications of mutations in human diseases. Jayasinghe et al. identify nearly 2,000 splice-site-creating mutations (SCMs) from over 8,000 tumor samples across 33 cancer types. They provide a more accurate interpretation of previously mis-annotated mutations, highlighting the importance of integrating data types to understand the functional and the clinical implications of splicing mutations in human disease.

Original languageEnglish (US)
Pages (from-to)270-281.e3
JournalCell Reports
Volume23
Issue number1
DOIs
StatePublished - Apr 3 2018

Fingerprint

Tumors
Mutation
Neoplasms
Bioelectric potentials
Bioinformatics
Genes
RNA
DNA
Missense Mutation
Computational Biology
Glioma

Keywords

  • mutations of clinical relevance
  • RNA
  • splicing

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Systematic Analysis of Splice-Site-Creating Mutations in Cancer. / The Cancer Genome Atlas Research Network.

In: Cell Reports, Vol. 23, No. 1, 03.04.2018, p. 270-281.e3.

Research output: Contribution to journalArticle

The Cancer Genome Atlas Research Network 2018, 'Systematic Analysis of Splice-Site-Creating Mutations in Cancer', Cell Reports, vol. 23, no. 1, pp. 270-281.e3. https://doi.org/10.1016/j.celrep.2018.03.052
The Cancer Genome Atlas Research Network. / Systematic Analysis of Splice-Site-Creating Mutations in Cancer. In: Cell Reports. 2018 ; Vol. 23, No. 1. pp. 270-281.e3.
@article{9d916b6c074a4dad9adcc53e5c6fba2d,
title = "Systematic Analysis of Splice-Site-Creating Mutations in Cancer",
abstract = "For the past decade, cancer genomic studies have focused on mutations leading to splice-site disruption, overlooking those having splice-creating potential. Here, we applied a bioinformatic tool, MiSplice, for the large-scale discovery of splice-site-creating mutations (SCMs) across 8,656 TCGA tumors. We report 1,964 originally mis-annotated mutations having clear evidence of creating alternative splice junctions. TP53 and GATA3 have 26 and 18 SCMs, respectively, and ATRX has 5 from lower-grade gliomas. Mutations in 11 genes, including PARP1, BRCA1, and BAP1, were experimentally validated for splice-site-creating function. Notably, we found that neoantigens induced by SCMs are likely several folds more immunogenic compared to missense mutations, exemplified by the recurrent GATA3 SCM. Further, high expression of PD-1 and PD-L1 was observed in tumors with SCMs, suggesting candidates for immune blockade therapy. Our work highlights the importance of integrating DNA and RNA data for understanding the functional and the clinical implications of mutations in human diseases. Jayasinghe et al. identify nearly 2,000 splice-site-creating mutations (SCMs) from over 8,000 tumor samples across 33 cancer types. They provide a more accurate interpretation of previously mis-annotated mutations, highlighting the importance of integrating data types to understand the functional and the clinical implications of splicing mutations in human disease.",
keywords = "mutations of clinical relevance, RNA, splicing",
author = "{The Cancer Genome Atlas Research Network} and Jayasinghe, {Reyka G.} and Song Cao and Qingsong Gao and Wendl, {Michael C.} and Vo, {Nam Sy} and Reynolds, {Sheila M.} and Yanyan Zhao and H{\'e}ctor Climente-Gonz{\'a}lez and Shengjie Chai and Fang Wang and Rajees Varghese and Mo Huang and Liang, {Wen Wei} and Wyczalkowski, {Matthew A.} and Sohini Sengupta and Zhi Li and Payne, {Samuel H.} and David Feny{\"o} and Miner, {Jeffrey H.} and Walter, {Matthew J.} and Caesar-Johnson, {Samantha J.} and Demchok, {John A.} and Ina Felau and Melpomeni Kasapi and Ferguson, {Martin L.} and Hutter, {Carolyn M.} and Sofia, {Heidi J.} and Roy Tarnuzzer and Zhining Wang and Liming Yang and Zenklusen, {Jean C.} and Zhang, {Jiashan (Julia)} and Sudha Chudamani and Jia Liu and Laxmi Lolla and Rashi Naresh and Todd Pihl and Qiang Sun and Yunhu Wan and Ye Wu and Juok Cho and Timothy DeFreitas and Scott Frazer and Nils Gehlenborg and Gad Getz and Heiman, {David I.} and Jaegil Kim and Baylin, {Stephen B} and Leslie Cope and Danilova, {Liudmila V}",
year = "2018",
month = "4",
day = "3",
doi = "10.1016/j.celrep.2018.03.052",
language = "English (US)",
volume = "23",
pages = "270--281.e3",
journal = "Cell Reports",
issn = "2211-1247",
publisher = "Cell Press",
number = "1",

}

TY - JOUR

T1 - Systematic Analysis of Splice-Site-Creating Mutations in Cancer

AU - The Cancer Genome Atlas Research Network

AU - Jayasinghe, Reyka G.

AU - Cao, Song

AU - Gao, Qingsong

AU - Wendl, Michael C.

AU - Vo, Nam Sy

AU - Reynolds, Sheila M.

AU - Zhao, Yanyan

AU - Climente-González, Héctor

AU - Chai, Shengjie

AU - Wang, Fang

AU - Varghese, Rajees

AU - Huang, Mo

AU - Liang, Wen Wei

AU - Wyczalkowski, Matthew A.

AU - Sengupta, Sohini

AU - Li, Zhi

AU - Payne, Samuel H.

AU - Fenyö, David

AU - Miner, Jeffrey H.

AU - Walter, Matthew J.

AU - Caesar-Johnson, Samantha J.

AU - Demchok, John A.

AU - Felau, Ina

AU - Kasapi, Melpomeni

AU - Ferguson, Martin L.

AU - Hutter, Carolyn M.

AU - Sofia, Heidi J.

AU - Tarnuzzer, Roy

AU - Wang, Zhining

AU - Yang, Liming

AU - Zenklusen, Jean C.

AU - Zhang, Jiashan (Julia)

AU - Chudamani, Sudha

AU - Liu, Jia

AU - Lolla, Laxmi

AU - Naresh, Rashi

AU - Pihl, Todd

AU - Sun, Qiang

AU - Wan, Yunhu

AU - Wu, Ye

AU - Cho, Juok

AU - DeFreitas, Timothy

AU - Frazer, Scott

AU - Gehlenborg, Nils

AU - Getz, Gad

AU - Heiman, David I.

AU - Kim, Jaegil

AU - Baylin, Stephen B

AU - Cope, Leslie

AU - Danilova, Liudmila V

PY - 2018/4/3

Y1 - 2018/4/3

N2 - For the past decade, cancer genomic studies have focused on mutations leading to splice-site disruption, overlooking those having splice-creating potential. Here, we applied a bioinformatic tool, MiSplice, for the large-scale discovery of splice-site-creating mutations (SCMs) across 8,656 TCGA tumors. We report 1,964 originally mis-annotated mutations having clear evidence of creating alternative splice junctions. TP53 and GATA3 have 26 and 18 SCMs, respectively, and ATRX has 5 from lower-grade gliomas. Mutations in 11 genes, including PARP1, BRCA1, and BAP1, were experimentally validated for splice-site-creating function. Notably, we found that neoantigens induced by SCMs are likely several folds more immunogenic compared to missense mutations, exemplified by the recurrent GATA3 SCM. Further, high expression of PD-1 and PD-L1 was observed in tumors with SCMs, suggesting candidates for immune blockade therapy. Our work highlights the importance of integrating DNA and RNA data for understanding the functional and the clinical implications of mutations in human diseases. Jayasinghe et al. identify nearly 2,000 splice-site-creating mutations (SCMs) from over 8,000 tumor samples across 33 cancer types. They provide a more accurate interpretation of previously mis-annotated mutations, highlighting the importance of integrating data types to understand the functional and the clinical implications of splicing mutations in human disease.

AB - For the past decade, cancer genomic studies have focused on mutations leading to splice-site disruption, overlooking those having splice-creating potential. Here, we applied a bioinformatic tool, MiSplice, for the large-scale discovery of splice-site-creating mutations (SCMs) across 8,656 TCGA tumors. We report 1,964 originally mis-annotated mutations having clear evidence of creating alternative splice junctions. TP53 and GATA3 have 26 and 18 SCMs, respectively, and ATRX has 5 from lower-grade gliomas. Mutations in 11 genes, including PARP1, BRCA1, and BAP1, were experimentally validated for splice-site-creating function. Notably, we found that neoantigens induced by SCMs are likely several folds more immunogenic compared to missense mutations, exemplified by the recurrent GATA3 SCM. Further, high expression of PD-1 and PD-L1 was observed in tumors with SCMs, suggesting candidates for immune blockade therapy. Our work highlights the importance of integrating DNA and RNA data for understanding the functional and the clinical implications of mutations in human diseases. Jayasinghe et al. identify nearly 2,000 splice-site-creating mutations (SCMs) from over 8,000 tumor samples across 33 cancer types. They provide a more accurate interpretation of previously mis-annotated mutations, highlighting the importance of integrating data types to understand the functional and the clinical implications of splicing mutations in human disease.

KW - mutations of clinical relevance

KW - RNA

KW - splicing

UR - http://www.scopus.com/inward/record.url?scp=85044896624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044896624&partnerID=8YFLogxK

U2 - 10.1016/j.celrep.2018.03.052

DO - 10.1016/j.celrep.2018.03.052

M3 - Article

VL - 23

SP - 270-281.e3

JO - Cell Reports

JF - Cell Reports

SN - 2211-1247

IS - 1

ER -